These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 36601347)
41. From acute SARS-CoV-2 infection to pulmonary hypertension. Eroume À Egom E; Shiwani HA; Nouthe B Front Physiol; 2022; 13():1023758. PubMed ID: 36601347 [TBL] [Abstract][Full Text] [Related]
42. COVID-19 patients may become predisposed to pulmonary arterial hypertension. Suzuki YJ; Nikolaienko SI; Shults NV; Gychka SG Med Hypotheses; 2021 Feb; 147():110483. PubMed ID: 33444904 [TBL] [Abstract][Full Text] [Related]
43. Mechanisms of Pulmonary Vasculopathy in Acute and Long-Term COVID-19: A Review. Riou M; Coste F; Meyer A; Enache I; Talha S; Charloux A; Reboul C; Geny B Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732160 [TBL] [Abstract][Full Text] [Related]
44. Pulmonary Hypertensive Changes Secondary to COVID-19 Pneumonia in a Chronically SARS-CoV-2-Infected Bilateral Lung Explant. Rohr JM; Strah H; Berkheim D; Siddique A; Radio SJ; Swanson BJ Int J Surg Pathol; 2022 Jun; 30(4):443-447. PubMed ID: 34894817 [TBL] [Abstract][Full Text] [Related]
45. At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease. Cascino TM; Desai AA; Kanthi Y Curr Opin Pulm Med; 2021 Sep; 27(5):342-349. PubMed ID: 34127622 [TBL] [Abstract][Full Text] [Related]
46. Right ventricular dysfunction and pulmonary hypertension in COVID-19: a meta-analysis of prevalence and its association with clinical outcome. Oktaviono YH; Mulia EPB; Luke K; Nugraha D; Maghfirah I; Subagjo A Arch Med Sci; 2022; 18(5):1169-1180. PubMed ID: 36160328 [TBL] [Abstract][Full Text] [Related]
47. Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. Abraham GR; Kuc RE; Althage M; Greasley PJ; Ambery P; Maguire JJ; Wilkinson IB; Hoole SP; Cheriyan J; Davenport AP J Mol Cell Cardiol; 2022 Jun; 167():92-96. PubMed ID: 35339512 [TBL] [Abstract][Full Text] [Related]
48. Trends and Risk Factors of In-Hospital Mortality of Patients with COVID-19 in Germany: Results of a Large Nationwide Inpatient Sample. Hobohm L; Sagoschen I; Barco S; Schmidtmann I; Espinola-Klein C; Konstantinides S; Münzel T; Keller K Viruses; 2022 Jan; 14(2):. PubMed ID: 35215869 [TBL] [Abstract][Full Text] [Related]
50. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Kundu R; Narean JS; Wang L; Fenn J; Pillay T; Fernandez ND; Conibear E; Koycheva A; Davies M; Tolosa-Wright M; Hakki S; Varro R; McDermott E; Hammett S; Cutajar J; Thwaites RS; Parker E; Rosadas C; McClure M; Tedder R; Taylor GP; Dunning J; Lalvani A Nat Commun; 2022 Jan; 13(1):80. PubMed ID: 35013199 [TBL] [Abstract][Full Text] [Related]
51. Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19. Willems LH; Nagy M; Ten Cate H; Spronk HMH; Groh LA; Leentjens J; Janssen NAF; Netea MG; Thijssen DHJ; Hannink G; van Petersen AS; Warlé MC Thromb Res; 2022 Jan; 209():106-114. PubMed ID: 34922160 [TBL] [Abstract][Full Text] [Related]
52. Pulmonary arterial hypertension and right ventricular systolic dysfunction in COVID-19 survivors. Rossi R; Coppi F; Monopoli DE; Sgura FA; Arrotti S; Boriani G Cardiol J; 2022; 29(1):163-165. PubMed ID: 34897638 [No Abstract] [Full Text] [Related]
53. Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. Halawa S; Pullamsetti SS; Bangham CRM; Stenmark KR; Dorfmüller P; Frid MG; Butrous G; Morrell NW; de Jesus Perez VA; Stuart DI; O'Gallagher K; Shah AM; Aguib Y; Yacoub MH Nat Rev Cardiol; 2022 May; 19(5):314-331. PubMed ID: 34873286 [TBL] [Abstract][Full Text] [Related]
54. Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections. Kennedy AE; Cook L; Breznik JA; Cowbrough B; Wallace JG; Huynh A; Smith JW; Son K; Stacey H; Ang J; McGeer A; Coleman BL; Larché M; Larché M; Hambly N; Nair P; Ask K; Miller MS; Bramson J; Levings MK; Nazy I; Svenningsen S; Mukherjee M; Bowdish DME Viruses; 2021 Nov; 13(11):. PubMed ID: 34835045 [TBL] [Abstract][Full Text] [Related]
55. SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis. Yoo JS; Sasaki M; Cho SX; Kasuga Y; Zhu B; Ouda R; Orba Y; de Figueiredo P; Sawa H; Kobayashi KS Nat Commun; 2021 Nov; 12(1):6602. PubMed ID: 34782627 [TBL] [Abstract][Full Text] [Related]
56. Impact of persistent D-dimer elevation following recovery from COVID-19. Lehmann A; Prosch H; Zehetmayer S; Gysan MR; Bernitzky D; Vonbank K; Idzko M; Gompelmann D PLoS One; 2021; 16(10):e0258351. PubMed ID: 34710097 [TBL] [Abstract][Full Text] [Related]
57. Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021. Wang L; Wang Q; Davis PB; Volkow ND; Xu R World Psychiatry; 2022 Feb; 21(1):124-132. PubMed ID: 34612005 [TBL] [Abstract][Full Text] [Related]